Quality of life and patient preference for oral chemotherapy in metastatic colorectal carcinoma (MCRC): comparison of XELOX and FOLFOX4 regimens
| Authors | |
|---|---|
| Year of publication | 2008 |
| Type | Conference abstract |
| MU Faculty or unit | |
| Citation | |
| Description | We evaluated the quality of life of patients with MCRC and their preferences for oral vs. intravenous chemotherapy following treatment with either capecitabine + oxaliplatin (XELOX) or 5-FU/FA + oxaliplatin (FOLFOX4)A total of 80 patients were involved; 38 had received XELOX and 42 had received FOLFOX4. In the FOLFOX4 group, 35 (83%) patients stated that they would mostly prefer oral therapy. According to the Life Quality Questionnaire, 26 (60%) patients who had received FOLFOX4 selected neither contented nor discontented, rather discontented and/or discontented in their responses to individual categories. In the XELOX group, 35 (92%) patients stated that they would prefer oral therapy. According to the Life Quality Questionnaire, 34 (90%) of XELOX patients selected rather contented, contented and/or very contented as their response to individual categories. Only 4 (10%) patients in the XELOX group selected neutral or negative responses. Most patients prefer oral chemotherapy. Our results further suggest that the quality of life of most patients treated with an oral fluoropyrimidine-based chemotherapy regimen is good and better than that of patients treated with a regimen based on continuous intravenous infusional 5-FU/FA. |